Hypercalcemia of Malignancy in Adults
Key Points
Key Points
- Hypercalcemia of malignancy (HCM), a condition associated with high morbidity and mortality, is the most common metabolic complication of malignancies.
- All adults with HCM should receive treatment with denosumab (Dmab) or an intravenous (IV) bisphosphonate (BP).
- Adults with calcitriol-mediated HCM should first be treated with glucocorticoids, with the addition of Dmab or an IV BP if glucocorticoid therapy is insufficient.
Treatment
...reatment
...In adults with HCM, Endocrine Society (ES) reco...
...ecommendation 2In adults with HCM, ES su...
...dation 3In adults with severe HCM (ser...
...tion 4In adults with refractory/recurre...
...ion 5In adults with HCM from tumors associate...
Recommendation 6In adult patients with hypercalc...
...ion 7In adult patients with hypercalcemia due to...
...mmendation 8In adult patients with...
...od Practice Statements...
...adults with HCM, adequate hydration with IV f...
...with HCM, dental hygiene and oral healt...
...adults with HCM who receive antiresorptive t...
...with HCM, renal function (creatinine clearance [C...
...n adults with HCM and renal insuff...
UGPS 6In adults with HCM, serum magn...
...ults with HCM, clinical oncology con...
...PS 8In adults with hypercalcemia due t...
...able 1. Treatment Regimens for Hypercalcemia...
...ted Workflow for the Management of Hypercal...
...ndix A: Common Terminology Criteria for...